Compare Docusign Inc (DOCU) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Illumina, Inc. — how do they compare? Docusign Inc trades at $71 (market cap $12.88B), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 3.1× Docusign Inc's market cap, and Illumina, Inc. is more actively traded (2,948,626 versus 2,591,969). Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Illumina, Inc. for 83 Days on average.
| DOCU | ILMN | |
|---|---|---|
Market Cap | $12.88B | $40.43B |
Volume | 2,591,969 | 2,948,626 |
Sector | Technology | Health |
52-Week High | $73.14 | $293.69 |
52-Week Low | $41.75 | $91.00 |
Typical Hold Time | 71 Days | 83 Days |
Enterprise Value | $12.28B | $41.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 4.71% with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows robust revenue growth reaching $2.98B in 2025 with improving profit margins, though valuation ratios remain elevated. Recent news highlights AI integration in contract processing and leadership recognition in workflow software.
Outlook remains positive with projected revenue growth to $3.4B in 2026, supported by AI adoption and operating leverage. Risks include insider selling, competitive pressures, and high valuation multiples. Analyst consensus is cautious with 64% hold ratings, but technical strength and fundamental improvements suggest potential for continued upside if execution persists.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
